Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

Topical Finasteride doesn't directly reduce 5ar enzyme on scalp and has the same mechanism as oral, needing to go through the liver. Users debate the accuracy of this information and discuss various studies and experiences.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

Hair loss treatments, including Dutasteride 0.5mg daily, finasteride 1mg daily, minoxidil 5% 2x daily, dermarolling, low-level light therapy (LLLT), ketokonazole shampoo, and diet optimization; discussing their effectiveness and side effects.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.

A user created oral minoxidil sugar cubes due to lack of prescription access, leading to a humorous discussion about unconventional and potentially unsafe methods of using minoxidil. The conversation highlights the lengths people go to for hair growth.

A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The conversation discusses preferences for hair loss treatments, specifically finasteride over dutasteride. Users share personal experiences, cost considerations, FDA approval status, and potential side effects, with some switching between treatments to find what works best for them.

A user is seeking advice on hair loss treatment and has been prescribed finasteride. They currently use minoxidil, rosemary oil, and castor oil, and are considering adding dermarolling. Respondents suggest daily use of minoxidil and finasteride, with some recommending additional treatments like ketoconazole shampoo, dermapen, dutasteride, and vitamins.

The conversation discusses whether 2.5mg of dutasteride or 200mg of testosterone weekly is more influential in preventing hair loss, with various personal experiences indicating that the effectiveness is dependent on the individual's genetic profile. Some users report that dutasteride is likely to be more effective at the given doses.

The conversation discusses the potential benefits of sublingual minoxidil for hair loss treatment. It suggests that sublingual minoxidil, which bypasses the liver, may have fewer side effects, greater bioavailability, and could be more effective than oral minoxidil.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

A user reported significant hair improvement after one month of using dutasteride and oral minoxidil. Others expressed skepticism, attributing perceived changes to lighting and styling, and debated the effectiveness and risks of these treatments.

A user's experience with using Fin for hair loss, which includes shedding and regrowth, potential side effects, and the use of supplements, protein, and exercise as additional treatments.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.

A user stopped finasteride due to side effects and rapid hair loss, considering a hair system. Others suggested alternatives like dutasteride, minoxidil, and topical finasteride.

The conversation discusses switching from finasteride to dutasteride for hair loss treatment, with mixed experiences regarding shedding and effectiveness. Some users also mention using minoxidil and RU58841 alongside these treatments.

Increasing finasteride dosage can cause significant hair shedding initially. Users suggest adding minoxidil or switching to dutasteride for better results.

Sugary beverages increase the risk of pattern hair loss in men by 57%. Treatments discussed include Minoxidil, finasteride, and RU58841.

A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.

CumShotDiva's update on using topical minoxidil orally in an attempt to regrow hair, which has been met with both support and criticism from other users. The conversation includes discussion of possible side effects and the efficacy of this approach.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.